SHANGHAI – Hua Medicine Ltd. has received a nice endorsement from China's life science investors a month before the country's Spring Festival, closing $25 million in series B financing from some of the leading bio-focused venture capital firms, Frontline Bioventures and TF Capital. The latest financing was led by Ally Bridge Group, with all series A investors – Arch, Venrock, Fidelity, Wuxi Ventures and SAIL – chipping in for a second time.